# Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

> **NCT06551584** · PHASE1 · RECRUITING · sponsor: **Stanford University** · enrollment: 24 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
- Mixed Phenotype Acute Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** ORCA-T

## Key facts

- **NCT ID:** NCT06551584
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06551584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06551584, "Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06551584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*